American Superconductor Corporation (NasdaqGS: AMSC) a global power technologies company, announced on October 12, 2010 at the Solar Power International 2010 exhibition the launch of its SolarTie Grid Interconnection Solution. The SolarTie solution combines two of AMSC’s proven and proprietary technologies – D-VAR® STATCOM solutions and PowerModule™ power converter systems – that are today connecting over 15 gigawatts (GW) of renewable energy to the grid. This new offering is a utility-scale grid interconnection system designed specifically for megawatt-scale solar photovoltaic (PV) power plants. By coupling best-in-class power converter capabilities with AMSC’s world-renowned dynamic reactive compensation technology, the SolarTie product represents the industry’s first fully optimized solution for utility-scale PV power plant developers. The addressable market for SolarTie solutions is expected by industry analysts to be approximately $2 billion by 2015.
American Superconductor Corporation, a power technologies company, provides wind turbine designs and electrical control systems primarily in North America, Europe, and the Asia-Pacific.
Biogen Idec Inc. (NasdaqGS: BIIB) Drugmakers Roche and Biogen Idec Inc. said Friday October 15, 2010 that their drug candidate ocrelizumab met its goal in a mid-stage clinical trial, as it reduced brain lesions associated with multiple sclerosis compared to placebo.
The companies said that compared to placebo, patients who took a low dose of ocrelizumab had 89 percent fewer brain lesions, and patients who took a larger dose had 96 percent fewer lesions. Patients on ocrelizumab also had a larger reduction in flare-ups of their symptoms. The study lasted 24 weeks and involved 220 patients. The patients who were treated with ocrelizumab were given infusions at the start of the trial, and then a second infusion two weeks later.
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally.
Cubist Pharmaceuticals Inc. (NasdaqGS: CBST) said Thursday October 14, 2010 that its third-quarter net income grew 23 percent as sales of its antibiotic Cubicin increased. Cubist said its net income rose to $31.2 million, or 50 cents per share, from $25.4 million, or 42 cents per share, a year earlier. Cubicin is used to treat severe skin and bloodstream infections.
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States.
The Federal Trade Commission estimates that as many as 10 million Americans have their identities stolen each year. To help consumers fight against identity theft, Cintas Corporation (NasdaqGS:CTAS) has teamed up with the Council of Better Business Bureaus (CBBB) and the National Foundation for Credit Counseling (NFCC) as the national document management partner for the third annual Protect Your Identity Week. Beginning on Sunday, October 17, the week will consist of more than 175 identity theft education and protection events across the nation with free shredding services powered by Cintas at participating locations. For a list of all locations, please visit the map at www.ProtectYourIDNow.org.
In addition, on Saturday, October 23, in select cities, community members are invited to help break the Guinness World Record™ for most paper shredded in 24 hours. Anyone can participate by bringing personal documents they wish to have securely destroyed by Cintas to their local event. Participating cities include Irvine, Calif., Southfield, Mich. and Cherry Hill, N.J.
Cintas Corporation provides corporate identity uniforms and related business services in the United States and Canada. The company operates through four segments: Rental Uniforms and Ancillary Products; Uniform Direct Sales; First Aid, Safety, and Fire Protection Services; and Document Management Services.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.